ArticleTheranostics2020
The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Site-Specific Labeling of PD-L1 Fab through Disulfide Rebridging for ImmunoPET Imaging.Chemical & biomedical imaging · 2026Article
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload.ACS omega · 2026Article
- Fc-Engineering Improves PET Imaging of Anti-Mesothelin VH-Fc across Multiple Tumor Mouse Models and Reveals Sex-Specific Renal Clearance.Bioconjugate chemistry · 2026Article
- Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging.Npj imaging · 2025Review
- Harnessing Fc-Directed Bioconjugation for the Synthesis of Site-Specifically Modified Radioimmunoconjugates.Bioconjugate chemistry · 2025Article
- Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Exploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer.ACS pharmacology & translational science · 2024Article
- Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Site-specific bioconjugation and nuclear imaging.Current opinion in chemical biology · 2024Review
- Good practices forEJNMMI radiopharmacy and chemistry · 2024Review
- Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer.Molecular pharmaceutics · 2024Article
- First-in-Human Evaluation of Site-Specifically LabeledJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- Site-SpecificBioconjugate chemistry · 2023Article
- Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.European radiology · 2023Article
- Site-selective radiolabeling using mushroom tyrosinase and the strain-promoted oxidation-controlled 1,2-quinone cycloaddition.RSC advances · 2023Article
- Click chemistry: a transformative technology in nuclear medicine.Nature protocols · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Delphine VivierDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Kimberly FungDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Cindy RodriguezDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Pierre AdumeauDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Gary A UlanerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sai Kiran SharmaDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brian M ZeglisDepartment of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Hunter College · USMemorial Sloan Kettering Cancer Center · USCity University of New York · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MLeveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2MMemorial Sloan Kettering Small Animal Imaging ResearchR24CA083084 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI KOUTCHER, JASON ARTHUR · 1999 to 2006
$4.4MPretargeted Clinical Imaging of CA19.9 in Pancreatic CancerU01CA221046 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ZEGLIS, BRIAN MATTHEW · 2018 to 2022
$3.5MThe Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-TrastuzumabR01CA204167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ULANER, GARY ALLAN · 2016 to 2020
$3.4MNovel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6MPretargeted Radioimmunotherapy Based on Bioorthogonal Click ChemistryR00CA178205 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2015 to 2017
$747kNCI NIH HHS P30 CA008748NCI NIH HHS R00 CA178205NCI NIH HHS R01 CA204167NCI NIH HHS R01 CA240963NCI NIH HHS R24 CA083084NCI NIH HHS R35 CA232130NCI NIH HHS U01 CA221046
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntibodiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBreast NeoplasmsDeferoxamineErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoconjugatesMiceMice, NudePolysaccharidesPositron-Emission TomographyRadioisotopesRadiopharmaceuticalsAntibodiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDeferoxamineErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesImmunoconjugatespertuzumabPolysaccharidesRadioisotopesRadiopharmaceuticalsReceptors, IgGZirconiumZirconium-8989ZrglycansHER2immunoPETpertuzumabradioimmunoconjugatesite-specific
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.